Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 959

1.

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.

Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.

Transl Oncol. 2019 Aug 2;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. [Epub ahead of print]

2.

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer Med. 2019 Jul 30. doi: 10.1002/cam4.2423. [Epub ahead of print]

3.

Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.

Hojo T, Masuda N, Iwamoto T, Niikura N, Anan K, Aogi K, Ohnishi T, Yamauchi C, Yoshida M, Kinoshita T, Masuoka H, Sagara Y, Sakatani T, Kojima Y, Tsuda H, Kumamaru H, Miyata H, Nakamura S.

Breast Cancer. 2019 Jul 20. doi: 10.1007/s12282-019-00997-w. [Epub ahead of print]

PMID:
31327134
4.

Synthesis, SAR study, and biological evaluation of novel 2,3-dihydro-1H-imidazo[1,2-a]benzimidazole derivatives as phosphodiesterase 10A inhibitors.

Chino A, Honda S, Morita M, Yonezawa K, Hamaguchi W, Amano Y, Moriguchi H, Yamazaki M, Aota M, Tomishima M, Masuda N.

Bioorg Med Chem. 2019 Aug 15;27(16):3692-3706. doi: 10.1016/j.bmc.2019.07.010. Epub 2019 Jul 6.

PMID:
31301949
5.

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma.

Ota T, Masuda N, Matsui K, Yamada T, Tanaka N, Fujimoto S, Fukuoka M.

Intern Med. 2019 Jun 7. doi: 10.2169/internalmedicine.2554-18. [Epub ahead of print]

6.

Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M.

Breast Cancer. 2019 Sep;26(5):651. doi: 10.1007/s12282-019-00984-1.

PMID:
31168692
7.

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.

Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A.

Future Oncol. 2019 Jul;15(21):2489-2501. doi: 10.2217/fon-2019-0143. Epub 2019 May 29.

PMID:
31140297
8.

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M.

Breast Cancer. 2019 Sep;26(5):637-650. doi: 10.1007/s12282-019-00970-7. Epub 2019 May 24. Erratum in: Breast Cancer. 2019 Jun 5;:.

PMID:
31127500
9.

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.

Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M.

J Glob Oncol. 2019 May;5:1-19. doi: 10.1200/JGO.18.00173.

10.

A mathematical look at empathy.

Masuda N, Santos FC.

Elife. 2019 Apr 29;8. pii: e47036. doi: 10.7554/eLife.47036.

11.

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.

Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M.

ESMO Open. 2019 Feb 27;4(1):e000476. doi: 10.1136/esmoopen-2018-000476. eCollection 2019.

12.

Early Experiences of Transanal Endoscopic Microsurgery Using a Wound Retractor with Stable Pneumorectum for Rectal Neoplasia.

Yamaguchi S, Shida Y, Ihara K, Ogata H, Masuda N, Takita J, Shibasaki Y, Haga N, Nakajima M, Sasaki K, Tsuchioka T.

Am Surg. 2019 Mar 1;85(3):e142-e144. No abstract available.

PMID:
30947790
13.

Effect of ASP2205 fumarate, a novel 5-HT2C receptor agonist, on urethral closure function in rats.

Ishigami T, Ueshima K, Ukai M, Asai N, Takamatsu H, Yokono M, Takeda M, Masuda N.

J Pharmacol Sci. 2019 Apr;139(4):333-339. doi: 10.1016/j.jphs.2019.02.004. Epub 2019 Feb 27.

14.

Modulation of urinary frequency via type 1 lysophosphatidic acid receptors: Effect of the novel antagonist ASP6432 in conscious rats.

Sakamoto K, Noguchi Y, Ueshima K, Ohtake A, Sato S, Imazumi K, Takeda M, Masuda N.

Eur J Pharmacol. 2019 Jun 15;853:11-17. doi: 10.1016/j.ejphar.2019.03.011. Epub 2019 Mar 7.

PMID:
30853531
15.

Effects of concentration of amyloid β (Aβ) on viability of cultured retinal pigment epithelial cells.

Masuda N, Tsujinaka H, Hirai H, Yamashita M, Ueda T, Ogata N.

BMC Ophthalmol. 2019 Mar 8;19(1):70. doi: 10.1186/s12886-019-1076-3.

16.

[Prostate Cancer Diagnosed during Androgen Replacement Therapy for Late-Onset Hypogonadism Treatment: A Case Report].

Sunada T, Hama Y, Ikeuchi R, Funada S, Masuda N, Yoshikawa T, Yoshida T, Hataya Y, Komatsu Y, Segawa T.

Hinyokika Kiyo. 2018 Dec;64(12):501-504. doi: 10.14989/ActaUrolJap_64_12_501. Japanese.

PMID:
30831666
17.

[A Case of Metastatic Clear Cell Renal Cell Carcinoma Showing Long-Term Complete Response after the Discontinuation of Tyrosine Kinase Inhibitor].

Hayata N, Yoshida T, Hama Y, Sunada T, Masuda N, Yoshikawa T, Satogami N, Segawa T.

Hinyokika Kiyo. 2018 Dec;64(12):483-487. doi: 10.14989/ActaUrolJap_64_12_483. Japanese.

PMID:
30831663
18.

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR.

Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M.

Int J Mol Sci. 2019 Feb 24;20(4). pii: E984. doi: 10.3390/ijms20040984.

19.

Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.

Masuda N, Ohe Y, Gemma A, Kusumoto M, Yamada I, Ishii T, Yamamoto N.

Cancer Sci. 2019 Apr;110(4):1401-1407. doi: 10.1111/cas.13977. Epub 2019 Mar 21.

20.

Atypical intrinsic neural timescale in autism.

Watanabe T, Rees G, Masuda N.

Elife. 2019 Feb 5;8. pii: e42256. doi: 10.7554/eLife.42256.

21.

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.

Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.

PMID:
30703739
22.

Detecting sequences of system states in temporal networks.

Masuda N, Holme P.

Sci Rep. 2019 Jan 28;9(1):795. doi: 10.1038/s41598-018-37534-2.

23.

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM.

Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012.

24.

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.

Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Wanifuchi-Endo Y, Hosoda M, Doihara H, Yamashita H.

Oncol Lett. 2019 Feb;17(2):2177-2186. doi: 10.3892/ol.2018.9853. Epub 2018 Dec 19.

25.

Multiscale core-periphery structure in a global liner shipping network.

Kojaku S, Xu M, Xia H, Masuda N.

Sci Rep. 2019 Jan 23;9(1):404. doi: 10.1038/s41598-018-35922-2.

26.

DS86760016, a Leucyl-tRNA Synthetase Inhibitor with Activity against Pseudomonas aeruginosa.

Kumar M, Rao M, Purnapatre KP, Barman TK, Joshi V, Kashyap A, Chaira T, Bambal RB, Pandya M, Khodor SA, Upadhyay DJ, Masuda N.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02122-18. doi: 10.1128/AAC.02122-18. Print 2019 Apr.

PMID:
30670430
27.

ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction.

Sakamoto K, Noguchi Y, Imazumi K, Ueshima K, Ohtake A, Takeda M, Masuda N.

Eur J Pharmacol. 2019 Mar 15;847:83-90. doi: 10.1016/j.ejphar.2019.01.014. Epub 2019 Jan 15.

PMID:
30658116
28.

Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.

Gemma A, Kusumoto M, Kurihara Y, Masuda N, Banno S, Endo Y, Houzawa H, Ueno N, Ohki E, Yoshimura A.

J Thorac Oncol. 2019 Apr;14(4):672-682. doi: 10.1016/j.jtho.2018.11.022. Epub 2018 Dec 3.

PMID:
30521972
29.

Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.

Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M.

Int J Clin Oncol. 2019 Mar;24(3):274-287. doi: 10.1007/s10147-018-1353-9. Epub 2018 Dec 4.

30.

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.

Masuda N, Inoue K, Nakamura R, Rai Y, Mukai H, Ohno S, Hara F, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Huang X, Iwata H.

Int J Clin Oncol. 2019 Mar;24(3):262-273. doi: 10.1007/s10147-018-1359-3. Epub 2018 Nov 3.

31.

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M.

N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.

PMID:
30345905
32.

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.

Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH.

Eur J Cancer. 2018 Nov;104:21-31. doi: 10.1016/j.ejca.2018.08.011. Epub 2018 Oct 8.

33.

Pharmacokinetics and toxicokinetics of d-serine in rats.

Hasegawa H, Masuda N, Natori H, Shinohara Y, Ichida K.

J Pharm Biomed Anal. 2019 Jan 5;162:264-271. doi: 10.1016/j.jpba.2018.09.026. Epub 2018 Sep 14.

PMID:
30268994
34.

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.

Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y.

Breast Cancer Res Treat. 2019 Jan;173(1):123-133. doi: 10.1007/s10549-018-4964-y. Epub 2018 Sep 21.

35.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J.

Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18.

PMID:
30241001
36.

Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.

Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M.

Breast Cancer Res Treat. 2018 Dec;172(3):611-618. doi: 10.1007/s10549-018-4958-9. Epub 2018 Sep 7.

PMID:
30194511
37.

Configuration model for correlation matrices preserving the node strength.

Masuda N, Kojaku S, Sano Y.

Phys Rev E. 2018 Jul;98(1-1):012312. doi: 10.1103/PhysRevE.98.012312.

PMID:
30110768
38.

Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.

Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S.

Eur J Cancer. 2018 Sep;101:123-133. doi: 10.1016/j.ejca.2018.05.017. Epub 2018 Jul 25.

PMID:
30053671
39.

Severe panuveitis with relapsing polychondritis.

Masuda N, Nishikawa R, Ueda T, Ogata N.

Am J Ophthalmol Case Rep. 2018 Apr 20;11:3-5. doi: 10.1016/j.ajoc.2018.04.024. eCollection 2018 Sep.

40.

Case report of a dose-volume histogram analysis of rib fracture after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study.

Yoshida K, Otani Y, Nose T, Yoden E, Asahi S, Tsukiyama I, Dokiya T, Saeki T, Fukuda I, Sekine H, Kumazaki Y, Takahashi T, Kotsuma T, Masuda N, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M.

J Contemp Brachytherapy. 2018 Jun;10(3):274-278. doi: 10.5114/jcb.2018.76983. Epub 2018 Jun 30.

41.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S.

Jpn J Clin Oncol. 2018 Sep 1;48(9):855-859. doi: 10.1093/jjco/hyy097.

PMID:
30020510
42.

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study.

Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M.

Breast Cancer (Auckl). 2018 Jul 5;12:1178223418786243. doi: 10.1177/1178223418786243. eCollection 2018.

43.

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1600. [Epub ahead of print]

44.

Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation.

Sakamoto K, Noguchi Y, Ueshima K, Yamakuni H, Ohtake A, Sato S, Ishizu K, Hosogai N, Kawaminami E, Takeda M, Masuda N.

J Pharmacol Exp Ther. 2018 Aug;366(2):390-396. doi: 10.1124/jpet.118.247908. Epub 2018 Jun 8.

PMID:
29884626
45.

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.

Nakahara Y, Fukui T, Shirasawa M, Harada S, Kusuhara S, Takakura A, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Masuda N, Inukai M, Sekiguchi T, Naoki K.

Intern Med. 2018 Nov 1;57(21):3149-3152. doi: 10.2169/internalmedicine.9884-17. Epub 2018 Jun 6.

46.

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.

Niwa H, Nakahara Y, Sasaki J, Masuda N.

BMJ Case Rep. 2018 Jun 4;2018. pii: bcr-2017-219770. doi: 10.1136/bcr-2017-219770.

47.

Effect of DS-2969b, a novel GyrB inhibitor, on rat and monkey intestinal microbiota.

Kumar M, Mathur T, Joshi V, Upadhyay DJ, Inoue SI, Masuda N.

Anaerobe. 2018 Jun;51:120-123. doi: 10.1016/j.anaerobe.2018.04.017. Epub 2018 May 2.

PMID:
29758524
48.

A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor.

Dennie J, Vandell AG, Inoue S, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Uchiyama M, Yamada M, Senaldi G.

J Clin Pharmacol. 2018 Dec;58(12):1557-1565. doi: 10.1002/jcph.1151. Epub 2018 May 10.

PMID:
29746725
49.

A generalised significance test for individual communities in networks.

Kojaku S, Masuda N.

Sci Rep. 2018 May 9;8(1):7351. doi: 10.1038/s41598-018-25560-z.

50.

Population changes in residential clusters in Japan.

Sekiguchi T, Tamura K, Masuda N.

PLoS One. 2018 May 9;13(5):e0197144. doi: 10.1371/journal.pone.0197144. eCollection 2018.

Supplemental Content

Loading ...
Support Center